Trial Profile
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Carboplatin; Etoposide; Ifosfamide
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 19 Mar 2024 Status changed from active, no longer recruiting to completed.
- 30 Oct 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2025.
- 30 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2025.